NCT02029573View on ClinicalTrials.gov

Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 1, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Glioblastoma Multiforme
Interventions
DRUG

Atorvastatin

80 mg po daily until disease progression or unacceptable toxicity. (starting dose of 40 mg po daily for the first 21 days)

DRUG

Temozolomide

75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy

RADIATION

Radiotherapy

60 Gy in 30 fractions

Trial Locations (1)

11525

King Fahad Medical City, Riyadh

All Listed Sponsors
lead

King Fahad Medical City

OTHER_GOV

NCT02029573 - Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma | Biotech Hunter | Biotech Hunter